Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction.

ABSTRACT:

Rationale

The majority of chronic obstructive pulmonary disease (COPD) patients have chronic bronchitis, for which specific therapies are unavailable. Acquired cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction is observed in chronic bronchitis, but has not been proven in a controlled animal model with airway disease. Furthermore, the potential of CFTR as a therapeutic target has not been tested in vivo, given limitations to rodent models of COPD. Ferrets exhibit cystic fibrosis-related lung pathology when CFTR is absent and COPD with bronchitis following cigarette smoke exposure.

Objectives

To evaluate CFTR dysfunction induced by smoking and test its pharmacological reversal by a novel CFTR potentiator, GLPG2196, in a ferret model of COPD with chr

SUBMITTER: Kaza N 

PROVIDER: S-EPMC10079430 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature